Pharvaris soars on mid-stage data for severe swelling condition, raises $300M

Pharvaris immediately announced the pricing of a $300 million offering on Wednesday after disclosing positive mid-stage data on its oral drug for a rare, inherited disorder that leads to severe swelling attacks.

The Swiss biotech said its twice-daily capsule for treating and preventing hereditary angioedema (HAE) attacks met the primary…
Click here to view original post